Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Iuliu Hatieganu University of Medicine and Pharmacy | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the therapeutic efficacy expressed in pharmacokinetic/pharmacodynamic (PK/PD) indices, the clinical response and the risk of adverse reactions following the continuous and intermittent administration of linezolid in critical patients in the Intensive Care Unit.
Subject inclusion criteria:
A minimum of 30 subjects in each group will be included in the study, in accordance with the study inclusion criteria:
Exclusion criteria:
Patients who have documented severe liver failure (Child-Pugh C score). Patients who refuse to sign the informed consent
The clinical study will be conducted in accordance with the protocol approved by the Ethics Commission of the "I.Haţieganu" University of Medicine and Pharmacy and the Ethics Commission of the Municipal Clinical Hospital, from Cluj-Napoca, in accordance with the rules of good clinical study practice.
The study will take place on the Intensive Care Unit of University Clinical Municipal Hospital from Cluj-Napoca, Romania. The analysis of blood drug concentration will be carried out at University of Medicine and Pharmacy 'Iuliu Hatieganu', Pharmacokinetics and Biopharmacy Laboratory, from Cluj-Napoca, Romania.
The objectives of the study are:
The study will be conducted in the ICU Department of the Municipal Clinical Hospital in Cluj-Napoca, Romania, following an open, prospective, randomized design, with two groups of patients (group with intermittent infusion and group with continuous infusion of the same daily dose of linezolid). The patients that will be included in each group will be the patients in need of intensive care who are prescribed linezolid by the attending physician, as empirical or targeted therapy.
Given the low light stability of the linezolid solution, the infusion bag will be protected with an opaque cover provided by the manufacturer throughout the infusion period. The administration will be carried out with the help of an infusomate.
The duration of the therapy will be established, for each patient, by the attending physician depending on the type, location and severity of the infection in accordance with the recommendations of the therapeutic guidelines.
Throughout the duration of the study, the subjects will receive the treatment according to the recommendations of the attending physician, regardless of the group they belong to, the only difference between the groups refers to the type of infusion used to administer linezolid.
Blood samples (10 samples) will be taken from each volunteer, according to the following schedule: immediately before the start of the infusion (T0) and at 1, 2, 4, 8, 12, 18, 24, 36, 48 hours from initiation of drug infusion. Then, a single daily sample will be taken until the end of the treatment. Blood samples will be used to determine plasma concentrations of linezolid.
The efficacy and safety of the treatment will be evaluated using clinical and paraclinical data which will be correlated with the pharmacokinetic parameters determined for each type of treatment (continuous infusion or intermittent infusion). The data will be recorded in a case report form without disclosing the identity of the patients (each patient will receive a code at the beginning of the study).
Each subject will be followed until discharge or a maximum of 30 days after initiation of therapy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Linezolid continuous infusion | Experimental | In the intervention arm, Linezolid is administered 600 mg as loading dose as an infusion lasting one hour (flow rate 300 ml/h), followed by continuous infusion of 1200 mg linezolid over 24 hours (flow rate 25 ml/h) which is immediately initiated. The continuous infusion is administered until the end of the treatment. |
|
| Linezolid Intermittent administration | Active Comparator | In the comparator arm, 600 mg dose of Linezolid is administered as one-hour infusion (flow rate 300 ml/h). Two doses at 12-h intervals are infused until the end of the treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Linezolid continuous infusion | Other | Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Linezolid plasmatic concentrations | 10 plasmatic concentrations in the first 48h of linezolid treatment, then 1 plasmatic concentration per day until the end of the treatment | first 2-14 days (during treatment) |
| Measure | Description | Time Frame |
|---|---|---|
| Linezolid clinical efficacy | Number of patients with negative cultures after linezolid treatment. Number of patients with laboratory improvement of leucocytes, c reactive protein, procalcitonin after linezolid treatment | from day 1 to day 30 after therapy initiation |
| Linezolid adverse reactions |
| Measure | Description | Time Frame |
|---|---|---|
| Linezolid drug-drug interactions | drug-drug interactions that are described in the summary of the product that may be seen | from day 1 to day 30 after therapy initiation |
| Determination of the minimum inhibitory concentration (MIC) for linezolid for the identified bacteria |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Constantin Bodolea, MD, PhD | Contact | +40726133845 | cbodolea@gmail.com | |
| Ligia A Hui, PharmD | Contact | +40740385801 | ligiahui@yahoo.com |
| Name | Affiliation | Role |
|---|---|---|
| Constantin Bodolea, MD, PhD | University Of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca | Principal Investigator |
| Ligia A Hui, PharmD | University Of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Clinical Municipal Hospital | Recruiting | Cluj-Napoca | Cluj | 400139 | Romania |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35453188 | Background | Hui LA, Bodolea C, Vlase L, Hiriscau EI, Popa A. Linezolid Administration to Critically Ill Patients: Intermittent or Continuous Infusion? A Systematic Literature Search and Review. Antibiotics (Basel). 2022 Mar 24;11(4):436. doi: 10.3390/antibiotics11040436. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
open, prospective, randomized design, with two groups of patients (group with intermittent administration and group with continuous administration of the same daily dose of linezolid).
Not provided
Not provided
Not provided
Not provided
side effects that are described in the summary of the product that may be seen |
| from day 1 to day 30 after therapy initiation |
The linezolid MIC for the gram positive bacteria identified will be assessed |
| from day 1 |
| Adina Popa, Prof PharmD | University Of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca | Study Chair |
| Laurian Vlase, Prof, PharmD | University Of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca | Study Chair |